

RESEARCH ARTICLE

Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans

Jennifer E. Huffman¹, Eva Albrecht², Alexander Teumer³, Massimo Mangino⁴, Karen Kapur^{5,6}, Toby Johnson⁷, Zoltán Kutalik^{5,6}, Nicola Pirastu^{8,9}, Giorgio Pistis¹⁰, Lorna M. Lopez^{11,12}, Toomas Haller¹³, Perttu Salo¹⁶, Anuj Goel¹⁷, Man Li¹⁸, Toshiko Tanaka¹⁹, Abbas Dehghan^{20,21}, Daniela Ruggiero²², Giovanni Malerba²³, Albert V. Smith^{24,25}, Ilja M. Nolte²⁶, Laura Portas²⁷, Amanda Phipps-Green²⁸, Lora Boteva¹, Pau Navarro¹, Asa Johansson^{29,30}, Andrew A. Hicks³¹, Ozren Polasek³², Tõnu Esko^{13,14,15}, John F. Peden¹⁷, Sarah E. Harris^{12,66}, Federico Murgia²⁷, Sarah H. Wild³³, Albert Tenesa^{1,34}, Adrienne Tin¹⁸, Evelin Mihailov¹³, Anne Grotevendt³⁵, Gauti K. Gislason²⁴, Josef Coresh^{18,36}, Pio D'Adamo^{8,9}, Sheila Ulivi⁸, Peter Vollenweider³⁷, Gerard Waeber³⁷, Susan Campbell¹, Ivana Kolcic³², Krista Fisher¹³, Margus Viigimaa^{38,39}, Jeffrey E. Metter¹⁹, Corrado Masciullo¹⁰, Elisabetta Trabetti²³, Cristina Bombieri²³, Rossella Sorice²², Angela Döring^{40,41}, Eva Reischl^{40,42}, Konstantin Strauch^{2,43}, Albert Hofman^{20,21}, Andre G. Uitterlinden^{20,21}, Melanie Waldenberger^{40,42}, H-Erich Wichmann^{41,43,44}, Gail Davies^{11,12}, Alan J. Gow^{11,12}, Nicola Dalbeth⁴⁵, Lisa Stamp⁴⁶, Johannes H. Smit⁴⁷, Mirna Kirin³³, Ramaiah Nagaraja⁴⁸, Matthias Nauck³⁵, Claudia Schurmann³, Kathrin Budde³⁵, Susan M. Farrington¹, Evropi Theodoratou³³, Antti Jula⁴⁹, Veikko Salomaa¹⁶, Cinzia Sala¹⁰, Christian Hengstenberg⁵⁰, Michel Burnier⁵¹, Reedik Mägi¹³, Norman Klopp⁴³, Stefan Kloiber⁵², Sabine Schipf⁵³, Samuli Ripatti^{49,54,55}, Stefano Cabras^{56,57}, Nicole Soranzo⁵⁴, Georg Homuth³, Teresa Nutile²², Patricia B. Munroe⁷, Nicholas Hastie¹, Harry Campbell³³, Igor Rudan^{32,33}, Claudia Cabrera⁵⁸, Chris Haley^{1,34}, Oscar H. Franco^{20,21}, Tony R. Merriman²⁸, Vilmundur Gudnason^{24,25}, Mario Pirastu²⁷, Brenda W. Penninx^{59,60,61}, Harold Snieder²⁶, Andres Metspalu¹³, Marina Ciullo²², Peter P. Pramstaller³¹, Cornelia M. van Duijn⁶⁰, Luigi Ferrucci¹⁹, Giovanni Gambaro⁶², Ian J. Deary^{11,12}, Malcolm G. Dunlop¹, James F. Wilson³³, Paolo Gasparini^{8,9}, Ulf Gyllenstein³⁰, Tim D. Spector⁴, Alan F. Wright¹, Caroline Hayward¹, Hugh Watkins⁶³, Markus Perola^{13,16,55}, Murielle Bochud⁶⁴, W. H. Linda Kao^{18,36}, Mark Caulfield⁷, Daniela Toniolo¹⁰, Henry Völzke⁵³, Christian Gieger², Anna Köttgen^{18,65}, Veronique Vitart^{1*}



OPEN ACCESS

Citation: Huffman JE, Albrecht E, Teumer A, Mangino M, Kapur K, Johnson T, et al. (2015) Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans. *PLoS ONE* 10(3): e0119752. doi:10.1371/journal.pone.0119752

Academic Editor: Dana C Crawford, Case Western Reserve University, UNITED STATES

Received: May 13, 2014

Accepted: February 3, 2015

Published: March 26, 2015

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](http://creativecommons.org/licenses/by/4.0/) public domain dedication.

Data Availability Statement: The top results of all the GWAMAs are available in the supplementary material. The complete meta-analysis and individual study GWAS results for the discovery studies has been deposited in DATASHARE, an open access digital repository at the University of Edinburgh (<http://dx.doi.org/10.7488/ds/212>).

Funding: Each individual study source of funding is listed as follows: AGES Reykjavik Study—The Age, Gene/Environment Susceptibility Reykjavik Study has been funded by NIH contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the

1 Medical Research Council (MRC) Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine (IGMM), University of Edinburgh, Edinburgh, United Kingdom, 2 Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany, 3 Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany, 4 King's College London, St. Thomas' Hospital Campus, London, United Kingdom, 5 Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland, 6 Swiss Institute of Bioinformatics, Lausanne, Switzerland, 7 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 8 Institute for Maternal and Child Health—Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) "Burlo Garofolo", Trieste, Italy, 9 University of Trieste, Trieste, Italy, 10 Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy, 11 Department of Psychology, The University of Edinburgh, Edinburgh, United Kingdom, 12 Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, Edinburgh, United Kingdom, 13 Estonian Genome Center, University of Tartu, Tartu, Estonia, 14 Broad Institute, Cambridge, MA, United States of America, 15 Children's Hospital Boston, Boston, MA, United States of America, 16 Department of Chronic Disease Prevention, National Institute for Health and Welfare (THL), Helsinki, Finland, 17 Department of Cardiovascular Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 18 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America, 19 Clinical Research Branch, National Institute on Aging, Baltimore, MD, United States of America, 20 Member of Netherlands Consortium for Healthy Aging (NCHA) sponsored by Netherlands Genomics Initiative (NGI), Leiden, The Netherlands,

Icelandic Parliament). ARIC—The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. AK was supported by the Emmy Noether Programme of the German Research Foundation (KO3598/2-1). Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. BLSA—The Baltimore Longitudinal Study of Aging was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. A portion of that support was through an R&D contract with MedStar Research Institute. BRIGHT—The BRIGHT study was supported by the Medical Research Council of Great Britain (G9521010D) and the Wellcome Trust as part of the Wellcome Trust Case Control Consortium. CoLaus—Cohorte Lausannoise (CoLaus) study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (33CSO-122661). CROATIA-Korcula—This research was funded by Grants from the Medical Research Council (UK) to Prof. Alan Wright, from the Republic of Croatia Ministry of Science, Education and Sports to Prof. Igor Rudan (108-1080315-0302) and an EU framework 6 project EUROSPAN (contract no. LSHG-CT-2006-018947) to Prof. Harry Campbell. CROATIA-Vis—This research was funded by Grants from the Medical Research Council (UK) to Prof. Alan Wright and from the Republic of Croatia Ministry of Science, Education and Sports to Prof. Igor Rudan (108-1080315-0302). ERF—The genotyping for the Erasmus Ruchphen Family (ERF) Study was founded by EUROSPAN (European Special Populations Research Network) and the European Commission FP6 STRP grant (018947; LSHG-CT-2006-018947). The ERF study was supported by grants from The Netherlands Organisation for Scientific Research (Pionier, 047.016.009, 047.017.043), Erasmus MC, the Centre for Medical Systems Biology (CMSB, National Genomics Initiative) and the Netherlands Brain Foundation (HersenStichting Nederland). EGCUT—The Estonian Genome Center of University of Tartu (EGCUT) received support from EU FP7 grant BBMRI-LPC 313010, targeted financing from Estonian Government IUT20-60, IUT24-6, Estonian Research Roadmap through the Estonian Ministry of

21 Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands, 22 Institute of Genetics and Biophysics "A. Buzzati-Traverso"—Consiglio Nazionale delle Ricerche (CNR), Naples, Italy, 23 Biology and Genetics section, Department of Life and Reproduction Sciences, University of Verona, Verona, Italy, 24 Icelandic Heart Association Research Institute, Kopavogur, Iceland, 25 University of Iceland, Reykjavik, Iceland, 26 Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 27 Institute of Population Genetics, National Research Council of Italy, Sassari, Italy, 28 Department of Biochemistry, University of Otago, Dunedin, New Zealand, 29 Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden, 30 Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, 751 85, Sweden, 31 Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy; Affiliated Institute of the University of Lübeck, Lübeck, Germany, 32 Faculty of Medicine, University of Split, Croatia, Soltanska 2, Split, 21000, Croatia, 33 Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom, 34 Roslin Institute, The University of Edinburgh, Edinburgh, United Kingdom, 35 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany, 36 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, United States of America, 37 Department of Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland, 38 Tallinn University of Technology, Department of Biomedical Engineering, Chair of Medical Physics, Tallinn, Estonia, 39 Centre of Cardiology, North Estonia Medical Centre, Tallinn, Estonia, 40 Institute of Epidemiology II, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany, 41 Institute of Epidemiology I, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany, 42 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany, 43 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-University, Munich, Germany, 44 Klinikum Grosshadern, Munich, Germany, 45 Bone and Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand, 46 Department of Medicine, University of Otago, Christchurch, New Zealand, 47 Department of Psychiatry/EMGO Institute, VU University Medical Centre, Amsterdam, the Netherlands, 48 Laboratory of Genetics, National Institute on Aging (NIA), Baltimore, MD, United States of America, 49 Department of Chronic Disease Prevention, National Institute for Health and Welfare (THL), Turku, Finland, 50 University Hospital Regensburg, Regensburg, Germany, 51 Department of Medicine, Nephrology Division, Lausanne University Hospital, Lausanne, Switzerland, 52 Max Planck Institute of Psychiatry, Munich, Germany, 53 Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, 54 Human Genetics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 55 University of Helsinki, Institute of Molecular Medicine, Helsinki, Finland, 56 Department of Mathematics and Informatics, Università di Cagliari, Cagliari, Italy, 57 Department of Statistics, Universidad Carlos III de Madrid, Madrid, Spain, 58 Queen Mary, University of London, London, United Kingdom, 59 Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands, 60 Department of Epidemiology, Subdivision Genetic Epidemiology, Erasmus MC, Rotterdam, The Netherlands, 61 Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands, 62 Institute of Internal Medicine, Renal Program, Columbus-Gemelli University Hospital, Catholic University, Rome, Italy, 63 on behalf of PROCARDIS; Department of Cardiovascular Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 64 University Institute of Social and Preventive Medicine, Lausanne, Switzerland, 65 Renal Division, Freiburg University Hospital, Freiburg, Germany, 66 Medical Genetics Section, University of Edinburgh Centre for Genomics and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom

* veronique.vitart@igmm.ed.ac.uk

Abstract

We tested for interactions between body mass index (BMI) and common genetic variants affecting serum urate levels, genome-wide, in up to 42569 participants. Both stratified genome-wide association (GWAS) analyses, in lean, overweight and obese individuals, and regression-type analyses in a non BMI-stratified overall sample were performed. The former did not uncover any novel locus with a major main effect, but supported modulation of effects for some known and potentially new urate loci. The latter highlighted a SNP at *RBFOX3* reaching genome-wide significant level (effect size 0.014, 95% CI 0.008-0.02,

Education and Research (3.2.0304.11-0312), Center of Excellence in Genomics (EXCEGEN), Development Fund from the University of Tartu (SP1GVARENG) and from an EFSD New Horizons grant. Health 2000—The Health 2000 study is funded by the National Institute for Health and Welfare (THL), the Finnish Centre for Pensions (ETK), the Social Insurance Institution of Finland (KELA), The Local Government Pensions Institution (KEVA) and other organizations listed on the website of the survey (<http://www.terveys2000.fi>). GWAS genotyping was supported by the Wellcome Trust Sanger Institute. Dr. Salomaa was supported by the Academy of Finland (grants # 129494 and 139635). InCHIANTI—The InCHIANTI study baseline (1998–2000) was supported as a “targeted project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U. S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336). INGI_CILENTO—This work was supported by grants from the EU (Vasoplus-037254), the Italian Ministry of Universities (FIRB –RBIN064YAT), the Assessorato Ricerca Regione Campania, the Ente Parco Nazionale del Cilento e Vallo di Diano and the Fondazione Banco di Napoli to Marina Ciullo. INGI-Carlantino and INGI-FVG—The study was funded by Regione FVG (L.26.2008). INGI-Val Borbera—The research was done using data obtained thanks to funds from Compagnia di San Paolo, Torino, Italy, Cariplo Foundation, Milano, Italy, Italian Ministry of Health Progetto Finalizzato 2007 and 2009 and project on Preventive Medicine 2010, and Prin 2009. KORA—The KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFN). The research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. LBC1936—Phenotype collection in the LBC1936 was supported by Age UK (The Disconnected Mind project). Genotyping was funded by the BBSRC. The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBSRC and Medical Research Council (MRC) is gratefully acknowledged. MICROS—In South Tyrol, the study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, and the South Tyrolean Sparkasse Foundation. NESDA—The infrastructure for the Netherlands Study of Depression and Anxiety (NESDA) was funded

$P_{\text{inter}} = 2.6 \times 10^{-8}$). Two top loci in interaction term analyses, *RBFOX3* and *ERO1LB-EDAR-ADD*, also displayed suggestive differences in main effect size between the lean and obese strata. All top ranking loci for urate effect differences between BMI categories were novel and most had small magnitude but opposite direction effects between strata. They include the locus *RBMS1-TANK* (men, $P_{\text{difflean-overweight}} = 4.7 \times 10^{-8}$), a region that has been associated with several obesity related traits, and *TSPYL5* (men, $P_{\text{difflean-overweight}} = 9.1 \times 10^{-8}$), regulating adipocytes-produced estradiol. The top-ranking known urate loci was *ABCG2*, the strongest known gout risk locus, with an effect halved in obese compared to lean men ($P_{\text{difflean-obese}} = 2 \times 10^{-4}$). Finally, pathway analysis suggested a role for N-glycan biosynthesis as a prominent urate-associated pathway in the lean stratum. These results illustrate a potentially powerful way to monitor changes occurring in obesogenic environment.

Introduction

Epidemiological studies have associated hyper- and hypo-uricemia with multiple common diseases and conditions in humans [1]; hyperuricemia clusters with all metabolic syndrome components and is a causal risk factor for gout development. To date, 28 loci have been identified and replicated accounting for about 7% of the inter-individual variation in age and sex adjusted serum urate (SU) levels [2]. The top two loci, which account for about half of the genetic variance explained so far, have been noted to display marked gender differences in their effect [3–6], while other urate loci not [2,7]. Variants in the solute carrier *SLC2A9* (also known as *GLUT9*) gene have doubled the effect on SU in women (0.40 standard deviation (sd) in [7]) than that observed in men, and variants in the transporter *ABCG2* gene have a stronger effect in men than in women (0.22 sd versus 0.14 sd in [7]).

Body mass index (BMI) is strongly positively correlated with SU levels in population-based studies (phenotypic correlations ranging from 0.27 to 0.44 [8–12]), and the relationship is approximately linear ([12] and S1 Fig.). Obesity is the strongest modifiable risk factor for hyperuricemia and gout [13]. We investigated here to what extent the genetic variants affecting SU are modulated by BMI. The fact that the genetic variants with the largest effect on SU levels are observed in genes encoding for ion transport proteins provides a biological rationale, since the activity of those transporters may be directly or indirectly affected by the metabolic changes associated with BMI increase, e.g. by levels of serum phosphate and hepatic ATP both reported to be inversely correlated with BMI [14,15]. Additionally, many of the newly discovered urate loci are in genes concerned with regulation of energy metabolism and glucose flux which are affected by BMI status. In 2008, a study had suggested that *SLC2A9* variants’ effects on SU may be stronger in severely obese individuals (defined as BMI > 40), with a stronger modulating BMI effect in men than in women [9], while a recent publication suggests the opposite, in a predominantly women study [16]. Both these studies had modest sample sizes, calling for a larger study to be carried out.

Here, we performed a genome-wide investigation for genetic variants influencing serum urate levels in a BMI-dependent fashion, primarily by analysing genome-wide association study (GWAS) stratified by BMI. Stratified analyses are best suited when main effects are very different in magnitude or direction between strata and if the environment factor measured on a continuous scale is not acting linearly. In a discovery set, totalling 41,832 participants, GWAS for SU were performed after stratifying subjects by BMI status categorized into three levels: lean (BMI < 25 kg/m²), overweight (25 ≤ BMI ≤ 30) and obese (BMI > 30 kg/m²). This

through the Geestkracht programme of the Dutch Scientific Organization (ZON-MW, grant number 10-000-1002) and matching funds from participating universities and mental health care organizations. Genotyping in NESDA was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health. Statistical analyses were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>), which is financially supported by the Netherlands Scientific Organization (I 480-05-003) along with a supplement from the Dutch Brain Foundation. NSPHS—The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical Research Council (project number K2007-66X-20270-01-3), and the Foundation for Strategic Research (SSF). The NSPHS as part of EUROSPAN (European Special Populations Research Network) was also supported by European Commission FP6 STRP grant number 01947 (LSHG-CT-2006-01947). This work was also supported by the Swedish Society for Medical Research (Åsa Johansson). Ogliastra Genetic Park (OGP)—This work was supported by grants from the Italian Ministry of Education, University and Research (MIUR) no.5571/DSPAR/2002 and (FIRB) D. M. no. 718/Ric/2005. ORCADES—ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, the Medical Research Council Human Genetics Unit and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947. PROCARDIS—The Procardis consortium was funded by EC Sixth Framework Programme (LSHM-CT- 2007- 037273) and Aztrazenneca AB. The authors acknowledge support from the Wellcome Trust core grant award 075491/Z/04. RS-I, RS-II—The GWA study was funded by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Consortium for Healthy Aging (NCHA) project nr. 050-060-810. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. German MediGRID and Services@MediGRID part of the German D-Grid, provided access to their grid resources. SHIP—The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the

allowed investigation of whether stratification revealed new genetic variants influencing SU and to systematically test differences in effects between BMI strata. Interaction between allelic effect and BMI was also investigated using a linear model with introduction of an interaction term and replication attempted in an independent set.

Materials and Methods

Study subjects

The discovery BMI-stratified genome-wide association study meta-analyses (GWAMA) combined data from 22 population cohorts encompassing 42741 individuals with measured circulating urate levels and BMI. With six additional follow-up studies, all were studies of European descent participants that contributed to the Global Urate and Gout consortium (GUGC) and have thus been previously described in detail [2]. The study-specific descriptions are reported in [S1 Table](#), in effect a subset of the GUGC publication.

Two extra studies, the Rotterdam study (described in [S1 Table](#) as also a GUGC participant) and a New-Zealand study of individuals from Polynesian descent [17] only contributed to the replication for the *CLK4* locus. Sample sizes for the different sub-analyses performed and urate summary statistics for all studies with break down per BMI and gender stratum are detailed in [S2 Table](#).

Genotype collection

Genome-wide SNP genotyping was undertaken by each cohort using various platforms as previously described [2] and reported in [S3 Table](#). Imputation of allele dosage of SNPs typed in the HapMap CEU population was performed using either MACH or IMPUTE with parameters and pre-imputation filters specified in [S3 Table](#).

Statistical analysis

BMI-stratified main effect GWAMA. Combined-gender and gender-separate association analyses were performed as described in Kolz *et al.* [7] within three body mass index (BMI) categories (nine sub-analyses performed in total): lean (BMI<25), overweight (25≤BMI≤30) and obese (BMI>30). Urate level (mg/dl) was adjusted for age, sex, and if required, ancestry principal components. Medications were not taken into account. Residuals were standardised using a z-score and used as response variable. Genome-wide association analyses were performed using imputed allele doses as predictor variable in linear models, and each study submitted regression summary statistics for meta-analysis. Studies with related individuals used a linear mixed model that additionally accounts for a polygenic random effect (e.g a score test mmscore [18] implemented in the GenABEL package [19]). Softwares used by the different studies to implement association testing are reported in [S3 Table](#).

The results from all individual GWA scans were combined into a fixed-effects meta-analysis using inverse variance weighting, implemented in the MetABEL R package [15]. From individual-study analysis, SNPs with minor allele frequency less than 1% or low imputation quality (assessed by the metrics r^2_{hat} (MACH) <0.3 or. info (IMPUTE) <0.4) were excluded. The QQ plots for association statistics from each study were visualised in R. This highlighted that two many results from the PROCARDIS-women dataset departed from the null hypothesis distribution, and this subset was removed from the final meta-analysis as driving many significant results if non-excluded. Study-specific genomic control inflation factors are reported in [S4 Table](#). In the meta-analyses, each individual study results were adjusted using the inflation factors; the overall meta-analysis effects' standard errors and p-value reported were not

Federal Ministry of Education and Research (grant nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg - West Pomerania. The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of the Siemens AG. SOCCS—The work was funded by the following grants: Cancer Research UK (C348/A12076, C348/A6361), Medical Research Council (G0000657-53203) and a Centre Grant from CORE as part of the Digestive Cancer Campaign. TwinsUK—The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust and King's College London. Tim Spector is holder of an ERC Advanced Principal Investigator award. NZPoly—The sample collection was funded by the New Zealand Health Research Council. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing Interests: The SHIP study had one commercial funding source "Siemens AG" but, as stated in the financial disclosure part, the funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript and therefore this does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

further corrected. The overall inflation factor for the nine stratified GWAMA were 1.0167 (lean-combined-gender), 1.0069 (lean-women), 1.0120 (lean-men), 1.0362 (overweight-combined-gender), 1.0167 (overweight-women), 1.0232 (overweight-men), 1.0157 (obese-combined-gender), 1.0180 (obese-women) and 1.0157 (obese-men). The conventional genome-wide significance threshold of 5×10^{-8} was used. To avoid results driven by one or two populations that are likely to be spurious, meta-analysis results for the lower allele frequency variants (MAF < 5%) are reported only if at least four populations contributed and if the contribution of any single study as calculated by the R package "meta" (<http://cran.r-project.org/>) was not greater than 30%. Annotation to known GWAS hits in the vicinity (window of 150 kb centred on index SNP) of novel potential urate loci was made using the NHGRI GWAS catalogue [20], 29-10-2013 update.

Main effect gene-based test. A gene-based test for SU association in the BMI-stratified GWAMA was conducted using the VEGAS software. Briefly, this method assigns SNPs to genes (+/- 50kb of 5' and 3' UTRs) and combines the association P-values accounting for linkage disequilibrium between markers assigned to the same gene. Analyses were conducted for each of the nine BMI/gender categories GWAMA results. As 17,787 genes are tested, the Bonferroni-corrected threshold for significance is set at 2.8×10^{-6} .

Replication of the differential effect of the *CLK4* variant rs7711186 was sought in six independent studies of individuals of European descent, totalling 1259 individuals, in which the marker was either genotyped or well imputed and, as exploratory foray, in a small sample of individuals of Polynesian descent (N = 290) with prevalent obesity.

Testing for differences in main effect between BMI strata. The meta-analysed SNP main effects on SU were compared between all pairwise BMI categories (lean-obese, lean-overweight, and overweight-obese) using a *t*-test. Test statistics were calculated using the statistic $t = (\beta_{\text{bmicat1}} - \beta_{\text{bmicat2}}) / \sqrt{(\text{SE}_{\text{bmicat1}}^2 + \text{SE}_{\text{bmicat2}}^2 - 2r(\text{SE}_{\text{bmicat1}} \text{SE}_{\text{bmicat2}}))}$, with β_{bmicat} and $\text{SE}_{\text{bmicat}}$ the meta-analysed SNP effect-estimates and their corresponding standard errors, and *r* the Spearman rank correlation coefficient between meta-analyzed beta-estimates, in each of the BMI categories compared, across all SNPs. Under the null hypothesis of no difference in effect sizes between BMI strata, the *t* statistic is expected to follow a Student's *t* distribution.

Interaction effect GWAMA

Discovery studies. Combined-gender and sex-stratified SNP by BMI interaction analyses were also performed in participating discovery studies using linear regression methods.

Urate residuals were generated using the same covariates and standardisation as described for the stratified main effect GWAS. For studies with related individuals, relatedness was accounted for by fitting ancestry principal components (PCs) derived from the genomic relationship matrix rather than fitting it in full within a mixed model for the association test as the iterative processes used for parameter estimations of the mixed models often did not converge in a pilot run using family-based populations. The number of PCs to account for, varying from study to study and best determined by examination of scree plots (point to which additional PCs all contribute the same percentage of genetic variation), was left to the decision of each study analyst. Each study GWAS was performed on imputed genotype dose using the following model: $z(\text{residual}) \sim \mu + \beta_1 \text{BMI} + \beta_2 \text{SNP} + \beta_{12} \text{BMI} * \text{SNP} + \epsilon$, with BMI as continuous variable, $z(\text{residual})$ the serum urate level adjusted for age, sex (in the combined gender analysis) and ancestry principal components expressed as *z*-score ((individual trait value minus population mean)/population standard deviation), β the regression coefficients for the fitted effects, ϵ the error term with normal probability distribution.

Softwares used by the different studies to implement association testing are reported in [S2 Table](#). Coefficients estimates for the main effect (β_1 and β_2) were not reported for studies that used Quicktest, as this later only reported the interaction term (β_{12}). Meta-analyses of the interaction effects (β_{12}) coefficients were carried out using MetABEL as described for the stratified main effect GWAS, with a higher MAF cut-off (5%) for each individual study. To avoid results predominantly driven by one population that are likely to be spurious, meta-analysis results with individual study contribution greater than 50% as calculated by the meta R package were filtered out.

As the individual studies genomic control inflation factors (λ) for these analyses were often high ([S3 Table](#)), only the studies with a λ less than 1.2 were analysed and sensitivity analyses with a reduced set of studies with λ less than 1.05 were also performed. The overall inflation factors for the GWAMA of interaction terms with the studies with a λ less than 1.2 corrected using genomic control were 0.992 in the combined-gender, 1.011 in the women and 1.024 in the men analyses.

Follow-up set. A small number of studies were available for follow-up of the linear interaction analysis, totalling 9298 participants (INGI-Cilento, OGP Talana, NESDA, INCIPE, INGI-FVG and AGES). All follow-up studies analyses were carried out in the combined-gender data-set only and use the “model-robust method” that is implemented in the ProbABEL and Quicktest packages. Application of the model-robust method in principle leads to lower genomic control inflation for the interaction term [21]. To increase sample size in the follow-up, the CoLaus study (N = 5411) was added as a follow-up rather than discovery set for the regression based interaction term analysis. One study (INCIPE-N = 940) had high λ for both main and interaction effects ([S3 Table](#)), and was not included in the meta-analysis.

Meta-analyses of the interaction effects (β_{12}) coefficients were carried out using MetABEL as previously described for the discovery cohorts. The overall inflation coefficient for this follow-up meta-analysis was 1.018 and 1.006 for the combined discovery and follow-up studies interaction term meta-analysis.

Pathway Analysis

The pathway analysis was carried out using a SNP-based circular permutation method implemented in an extension of the R package “genomicper” (<http://cran.r-project.org/>) available upon request to the package’s authors. After lift over to build37, SNPs were annotated to genes when they were located within gene regions using annotations from the NCBI Gene database (<http://www.ncbi.nlm.nih.gov/gene>; build.37.1) and the SNPs (and associated GWAMA-p-values) were ordered according to their location in the genome. Pathways (n = 229) were downloaded using KEGG.db (<http://www.genome.jp/kegg/>) and the SNPs and genes assigned to the pathways. SNPs with GWAMA p-values less or equal to 5% were considered associated with trait and associated SNPs within a pathway counted. This count was compared to the distribution of counts obtained from 10,000 circular permutations of the SNPs’ GWAMA association p-values with respect to the SNPs locations. In circular genomic permutation the genome is considered circular and ordered from chromosome 1 to 22 and restarting at chromosome 1 [22]. Each permutation is akin to the spinning of a wheel with the whole starting set of SNP labels and locations fixed at the outside of the wheel and the SNPs’ GWAMA p-values on the rotating wheel. As the SNPs’ p-values rotate to the same degree, they retain patterns of correlation similar to those in the original data. The empirical p-value for the trait-pathway association was calculated from the ratio of the total number of permutations with more significant SNPs than the non-permuted set divided by the total number of permutations performed in the analysis [22].

Ethics Statements

Participants gave written informed consent to each original study. All studies received approval from their local ethics committees as listed. [S1 Table](#) and protocols comply with the tenets of the Declaration of Helsinki.

Results

BMI stratified urate GWAS

All 22 participating studies had previously contributed to non-stratified SU analyses [2] and study-specific information is reported in [S1](#) and [S3](#) Tables. All study participants were of European ancestry and displayed BMI distribution typical of that of populations that adopted westernised diet and culture, with more than half of the participants overweight or obese ([Table 1](#)). The smallest stratum analysed comprised 4,613 individuals (obese-men category), the largest 17,078 (overweight-all category). Individual study SU descriptive statistics are reported in [S2 Table](#). The median population mean SU per stratum analysed was, as expected from the wealth of epidemiological data, higher in males than females and increasing from the lean to the obese group ([Table 1](#)).

The stratification process did not yield any novel genome-wide significant signal at the SNP level ($P < 5 \times 10^{-8}$) and all but three (*LRRC16*, *SLC16A9* and *RREB1*) of the eleven loci reported in two earlier, non-stratified, SU genome-wide association meta-analyses (GWAMA) of size roughly comparable to the present analyses [7,23], reached genome-wide significance in at least one of the nine strata ([Table 2](#)). All other loci encompassing SNP variant(s) with an association P-value below the suggestive threshold of 10^{-5} in any of the nine meta-analyses are listed in [S5 Table](#). Three of these suggestive loci, *AICF* (lean-combined-gender), *HLF* (obese-combined-gender) and *NRG4* (obese-men) are among the 18 novel, validated and replicated, urate loci in a large recent SU GWAMA ($N > 140,000$ individuals, a subset of which is analysed here) [2]. No functional link with urate homeostasis is obvious from the genes within the other suggestive signals apart potentially for *SLC28A1* (lean-men category), encoding a sodium/nucleoside co-transporter present in kidney. *MYO18D* and *ADAMST17* (both in lean stratum signals) have been previously listed as suggestive loci for serum urate levels in a small study of African American participants [24].

The gene-based association test implemented in the statistical package VEGAS revealed one novel locus, *CLK4*, reaching the gene-based genome-wide significance in the obese-men stratum only ($P\text{-value} = 2 \times 10^{-6}$, just below the Bonferroni corrected gene-based threshold of 2.8×10^{-6}). However, this effect was not reproduced in a replication set ([S2 Fig](#)).

A complete list of top associated genes in the gene based analysis is reported in [S6 Table](#) down to the suggestive threshold for gene-based association of 10^{-4} . Most encompassed known

Table 1. Statistics for the discovery studies mean serum urate levels.

	Lean (BMI < 25 kg/m ²)		Overweight (BMI 25–30kg/m ²)		Obese (BMI >30 kg/m ²)	
	median; Min-Max	N	median; Min-Max	N	median; Min-Max	N
All	4.58; 4.18–5.71	14504	5.36; 4.75–6.19	17078	5.81; 4.98–6.64	9445
Men	5.5; 4.86–6.19	5529	5.9; 5.2–6.72	10058	6.53; 5.31–7.23	4613
Women	4.1; 3.73–4.85	9753	4.6; 4.14–5.41	7189	5.22; 4.63–6.19	4690

Median, Minimum and Maximum values for the mean serum urate (SU) concentrations (mg/dl) amongst the twenty two studies used in the BMI and gender stratified meta-analyses are displayed. N represents the total number of participants analysed in each category.

doi:10.1371/journal.pone.0119752.t001

urate loci, including two of the recently reported novel urate-associated loci [2]: *AICF*, an essential component of the apolipoprotein B mRNA editing machinery, which is suggestive in the lean-combined sex stratum and *MLXIPL*, a carbohydrate-responsive element-binding protein, in the overweight-combined sex stratum.

Effect size variation across BMI strata for genome-wide significant effects

Some modulation of effect sizes depending on BMI status is suggested by close inspection of the most strongly associated SNPs in each stratum (Table 2). For example, a *GCKR* SNP, rs780094, reached genome-wide significance in the obese-combined-gender stratum but no SNP within that locus reached even the suggestive threshold of association (10^{-5}) in the lean-combined-gender stratum despite the larger number of individuals in the latter.

We formally tested the differences in SU effect sizes across BMI strata pairwise for the variants that reached the genome-wide significance threshold in at least one BMI stratum in this study (Table 2), discarding *SLC2A9* and *ABCG2* comparisons in the combined gender analysis as the proportion of male and female is not the same across BMI categories and the effect sizes of the variants are sex-sensitive. Taking a Bonferroni corrected significance threshold for the number of independent SNPs analysed in different settings ($0.05/(14 \times 3) = 0.0012$), only one locus, *ABCG2*, showed a statistically significant difference in effect size between obese and lean men (Table 2) and the trend between BMI categories and effect on SU level seemed linear (Fig. 1A). The magnitude of the effect on urate for the *ABCG2* index SNP was more than halved in the obese category compared to the lean category (effect of rs2231142 allelic substitution: 95% CI 0.257 to 0.389 in lean men versus 95% CI 0.069 to 0.213 in obese male) making the magnitude of effect in obese men similar to that seen in women (95% CI 0.125 to 0.221 in lean women). SNPs at three additional loci reached nominal significance (Fig. 1B-D).

Effect size variation across BMI strata genome-wide

The same tests were also done genome-wide to investigate potential BMI-sensitive SNPs of opposite effect between strata. QQ plots for those analyses (S3 Fig.) showed no evidence for an excess of false positive results (genomic inflation factors ranged from 1.004 to 1.016). The most significant effect-differences ($P_{\text{diff}} < 10^{-5}$) for all nine comparisons, after quality control for low frequency variants, are reported in S7 Table together with results for the 28 urate loci known to date, none of which reaching a P_{diff} lower than 10^{-5} . The lowest P-values were from the lean-obese and lean-overweight comparisons, all in loci not previously associated with urate and displaying different direction of effects in the lean and obese/overweight strata (Fig. 2 and S4 Fig.). The variant rs1829975, intergenic in *RBMS1-TANK*, a region that has been associated with several obesity related traits [25,26,27], reached the genome-wide significance threshold ($P_{\text{diff}} < 5 \times 10^{-8}$) in the men lean-overweight contrast. The second most significant difference, $P_{\text{diff}} = 9.13 \times 10^{-8}$, was also in the men lean-overweight contrast for a variant 5' of the gene *TSPYL5*, a gene coding the testis specific Y-encoded-like protein 5 that has been recently suggested to regulate estradiol produced by adipocytes [28]. The most significant loci for the lean-obese comparisons were intergenic *ARL5B-PLXDC2* and *LASS3* for the men (P_{diff} respectively, 1.1×10^{-7} and 2.2×10^{-7}) and *RBFOX3* for women and combined gender ($P_{\text{diff}} \sim 4 \times 10^{-7}$) which had suggestive main effect in the obese women stratum.

Interaction effect in linear regression models

To see whether a simple linear modelling of the BMI by SNP interaction (see methods) would uncover the same loci as the stratified analysis, interaction term analyses in linear models were

Table 2. Loci significantly associated with serum urate within any BMI stratum analysed and mean effect sizes across strata.

Locus	SNP ^a	Lean (BMI < 25 kg/m ²)				Overweight (BMI 25–30 kg/m ²)				Obese (BMI > 30 kg/m ²)				Effect size Comparison			
		A1	A2	fqA1	β _{lean}	s.e.	P	fqA1	β _{ov}	s.e.	P	fqA1	β _{ob}	s.e.	P	lean-ob	ov-ob
Combined-gender				N = 14504				N = 17078							N = 9445		
SLC2A9	rs7680126	G	A	0.22	-0.341	0.014	2.36E-134	0.22	-0.271	0.013	2.96E-92	0.21	-0.298	0.018	6.38E-62	NA	NA
ABCG2	rs2231142	G	T	0.89	-0.223	0.020	1.55E-29	0.89	-0.215	0.019	1.55E-30	0.89	-0.135	0.025	1.18E-07	NA	NA
SLC17A1;SLC17A4	rs1165209	G	A	0.46	-0.085	0.012	2.98E-13	0.46	-0.086	0.011	3.79E-15	0.46	-0.051	0.015	6.73E-04	9.35E01	7.05E-02
SLC22A11	rs2078267	C	T	0.49	0.064	0.012	7.13E-08	0.49	0.071	0.011	1.45E-10	0.49	0.042	0.015	5.81E-03	6.24E-01	2.51E-01
SLC22A12;NRXN2	rs10897518	C	T	0.32	0.060	0.012	1.49E-06	0.32	0.089	0.012	9.21E-14	0.32	0.069	0.016	2.27E-05	9.14E-01	6.66E-01
R3HDM2;INHBC	rs11172134	T	A	0.81	0.049	0.015	1.17E-03	0.81	0.078	0.014	3.78E-08	0.80	0.069	0.019	3.23E-04	1.66E-01	4.03E-01
near (5') PDZK1	rs1967017	C	T	0.53	-0.032	0.012	8.24E-03	0.53	-0.065	0.011	4.89E-09	0.53	-0.042	0.015	5.6E-03	3.86E-02	5.99E-01
GCKR	rs780094	C	T	0.59	-0.043	0.012	2.3E-04	0.59	-0.05	0.011	5.64E-06	0.60	-0.085	0.015	1.81E-08	6.50E-01	2.76E-02
Women				N = 9753				N = 7189							N = 4690		
SLC2A9	rs13129697	G	T	0.28	-0.403	0.015	7.57E-150	0.28	-0.412	0.018	2.66E-111	0.28	-0.376	0.023	3.12E-59	6.89E-01	3.28E-01
ABCG2	rs2231142	G	T	0.89	-0.173	0.024	5.56E-13	0.89	-0.190	0.028	2.39E-11	0.89	-0.114	0.037	1.75E-03	6.50E-01	1.78E-01
SLC17A1;SLC17A4	rs1165209	G	A	0.46	-0.096	0.014	1.20E-11	0.46	-0.087	0.017	1.89E-07	0.46	-0.049	0.021	2.18E-02	6.99E-01	6.34E-01
Men				N = 5529				N = 1058							N = 4613		
SLC2A9	rs16890979	C	T	0.75	0.254	0.022	1.15E-29	0.76	0.183	0.017	4.47E-26	0.76	0.176	0.026	8.66E-12	1.10E-02	2.25E-02
	rs10805346	C	T	0.44	-0.161	0.019	5.12E-17	0.43	-0.170	0.015	1.45E-31	0.44	-0.164	0.022	4.29E-14	6.83E-01	9.22E-01
ABCG2	rs2199936	G	A	0.90	-0.323	0.033	1.06E-22	0.89	-0.243	0.025	1.17E-22	0.89	-0.141	0.036	8.80E-05	5.15E-02	1.89E-04
SLC17A1;SLC17A4	rs1165196	G	A	0.46	-0.074	0.019	1.12E-04	0.46	-0.086	0.014	1.4E-09	0.46	-0.056	0.021	7.96E-03	6.03E-01	5.25E-01
SLC22A12;NRXN2	rs505802	C	T	0.31	0.065	0.021	1.95E-03	0.32	0.095	0.016	1.15E-09	0.31	0.078	0.023	7.76E-04	2.54E-01	6.76E-01

^aFor the same locus, the index SNP (i.e. with the lowest P-value) may vary across stratum and when not in high LD with each other (pairwise r^2 less than 0.5 using the SNAP proxy search tool HapMap2 reI22 data, <http://www.broadinstitute.org/mpg/snap/>) index SNPs are displayed separately. A1, allele for which effect (β) is reported, A2, alternate allele, fqA1 weighted average effect-allele frequency across the combined discovery studies. Mean effect sizes (β) are inverse-variance weighted estimates; s.e. standard error of the effect estimate. Effect differences were tested using a 2-sided t test. NA: non applied as the proportion of male and female is not the same across BMI categories and the variants' effect sizes sex-sensitive. P-value (P) reaching genome-wide significance threshold are indicated in bold. Abbreviations ov and ob stand for overweight and obese respectively.

doi:10.1371/journal.pone.0119752.t002





Fig 1. Mean effect across BMI strata of allelic substitutions at representative variants displaying genome-wide significant association with SU in at least one BMI stratum and displaying nominally significant difference in effect size across BMI strata. Effect size is on standardised age-adjusted SU levels. Error bars indicate the standard errors of the mean effect estimates within a BMI category. Horizontal lines indicate nominally significant ($p < 0.05$) differences in mean effect sizes between BMI categories, ** indicates significance at the 1% level taking into account the multiple comparisons performed. Differences in mean effect sizes between BMI strata were tested pairwise using the classical z-test, and P_{diff} denotes the 2-sided test corresponding P-value. Lean: BMI $< 25 \text{ kg/m}^2$, overweight: $25 \leq \text{BMI} \leq 30 \text{ kg/m}^2$, obese: BMI $> 30 \text{ kg/m}^2$.

doi:10.1371/journal.pone.0119752.g001

conducted in a subset of the discovery studies. Only those with an inflation factor less than 1.2 were combined in a meta-analysis. Two common variants, one intergenic *EROL1B-EDARADD* and one in the *RBFOX3* gene, displayed P-values just below the genome wide significance for a BMI*SNP interaction in the combined-sex analysis (rs10802528 $P_{inter} = 7.78 \times 10^{-8}$ and rs898534 $P_{inter} = 9 \times 10^{-8}$, Table 3 and full list of most significant results in S8 Table). SNPs at these loci also displayed suggestive interaction in the women-only analysis. The *ERO11B-EDARADD* locus remained suggestive in a sensitivity analysis with only the combined sex studies with the lowest genomic inflation analysed ($\lambda < 1.05$, S9 Table), while index SNP rs898534 in *RBFOX3*'s P-value drops to 1.5×10^{-4} . For a fair comparison, the tests for difference of main effects between BMI strata presented in S7 Table were recalculated using the exact subset of studies for which BMI*SNP term results were analysed (S9 Table) and led to similar conclusions. Noticeably, while the top loci in the lean versus obese comparisons come up as top loci in the linear fitting of an interaction term (S8 and S9 Tables), none of the loci ranking high in the lean versus overweight strata reached suggestive significance in the linear modelling despite the strongest P_{diff} P-values, suggesting a non-linear mode of action for those.

We attempted replication of the linear interaction seen in the combined-sex analysis in a replication set consisting of six studies. Model-robust estimates of effects' standard errors were calculated to avoid inflated λ_{GC} statistic commonly seen when using classical regression approaches [21]. Top results for this replication set and the combined samples are reported in

A. *RBMS1-TANK*; rs1829975 (C); MAF=16%; $P_{diff} = 4.71 \times 10^{-8}$



B. *TSPYL5*; rs16895559(C); MAF=5.3%; $P_{diff} = 9.13 \times 10^{-8}$




Fig 2. Forest plots of effect sizes within BMI stratum for variants with the two most significant mean effect size differences between BMI stratum. A. *RBMS1-TANK* locus and B. *TSPYL5* locus. The overall inverse—variance-weighted mean effect per BMI stratum is calculated assuming fixed effect across studies and represented by a lozenge, associated P-value displayed as P. Measure of heterogeneity between studies is reported (I-squared) with associated P-value for significance (p). P_{diff} is the test of difference in mean-effect size P-value. For study abbreviations and references, see [S1 Table](#).

doi:10.1371/journal.pone.0119752.g002

Table 3. Most significant BMI x SNP interaction terms for urate GWAMA.

Locus	SNP	A1	A2	chr	Pos(36)	fqA1	Discovery_Metaanalysis N = 28610				Replication_Metaanalysis N = 13959				Combined_Metaanalysis N = 42569			
							β_{inter}	s.e.	P_{inter}	I^2	β_{inter}	s.e.	P_{inter}	I^2	β_{inter}	s.e.	P_{inter}	I^2
<i>ERO1LB-EDARADD</i>	rs10802528	G	T	1	234573438	0.55	0.010	0.002	7.8E-08	0%	0.003	0.003	3.4E-01	0%	0.008	0.0015	2.94E-07	0%
<i>RBFOX3</i>	rs898534	G	A	17	74785108	0.88	-0.016	0.003	9 E-08	0%	-0.009	0.005	5.2E-2	0%	-0.014	0.003	2.61E-08	0%

A1, allele for which effect (β) is reported; A2 alternate allele, fqA1 weighted average effect-allele frequency across studies meta-analyzed; s.e. standard error of the effect estimate, I^2 meta-analysis heterogeneity statistic. The interaction term is modelled within a linear model where standardised SU levels (after adjustment for age and sex) is regressed on BMI, SNP and their interaction. β_{inter} is the regression coefficient for the interaction term.

doi:10.1371/journal.pone.0119752.t003

S9 Table. Both *RBFOX3* and *ERO1L-EDARADD* SNPs showed consistent direction of interaction effect between discovery and follow-up sets and a low level of heterogeneity across studies and *RBFOX3* index SNP reached genome-wide significance in the combined dataset ([Table 3](#)).

Pathway analysis

We used a recently developed pathway analysis method where pathway associations are tested following circular permutations of all the GWAS SNPs P-values [22] and compare enriched KEGG defined pathways in all nine strata. Results ([S10 Table](#)) did not uncover any pathway reaching the genome-wide significance threshold defined by a strict Bonferroni correction using 229 pathways and nine analyses ($P = 2.43 \times 10^{-5}$) but this threshold is very conservative given that many pathways are interconnected or overlapping and the combined and sex separate analyses are not independent. The most significant pathways were the ribosome pathway ($P = 3 \times 10^{-4}$) in overweight women, glycosaminoglycan degradation in obese men ($P = 6 \times 10^{-4}$) and N-glycan biosynthesis in lean women ($P = 6 \times 10^{-4}$).

N-glycan biosynthesis (KEGG pathway hsa00510- N = 43 genes) is particularly compelling as its ranking amongst associated pathways is stable through the variable sample sized analyses for the same BMI stratum: it ranks top in all the lean meta-analyses (rank = 1 in combined-gender and women, rank = 21 in men), while it is medium-ranked in all the overweight analyses (rank = 68 in combined-gender, rank = 69 in women and rank = 103 in men) and amongst the lowest ranks in all the obese strata (rank = 217 in combined-gender, rank = 223 women and rank = 218 men). The list of genes out of the 43 genes in this pathway with at least one SNP nominally significantly associated with urate levels ($P < 0.05$) in either BMI stratum in the combined-gender analyses are listed in [S11 Table](#).

Discussion

No novel locus with a genome-wide significant main effect on SU was uncovered when performing GWAS within the three BMI strata investigated, suggesting that changes in BMI do not switch on a yet unknown major urate locus. However, many loci reached suggestive level of SU association in a BMI dependent fashion and/or displayed suggestive difference in main effects across BMI categories that may collectively account for a substantial amount of BMI-sensitive SU variation.

One weakness of this study is its relatively modest size. Gene by environment (GxE) detection requires a larger sample-size than that required for the detection of main effects of comparable magnitude [29] (a rule of thumb proposed for case control design is a four time larger study [30]). Data from over 200,000 individuals were required to confirm the attenuation of FTO obesity risk genotype by physical activity [31] with the reported interaction term

significant, $P_{\text{inter}} = 0.001$, because only one candidate gene was tested. Few scans for GxE interaction have been performed genome-wide to date [32–37]. A stratification strategy was used to uncover novel women-specific genetic effects in waist-related phenotypes with strong statistical support using a very large dataset [36] and gave support for stronger effects of the known to date type 2 diabetes genetic risks variants in lean compared to obese individuals [35]. Other studies have reported modest (P_{inter} at best 10^{-4}) interaction effect after testing for a joint effect of the main SNP effect and interaction term with the significant results driven by the main SNP effect [32,34]. Joint effect meta-analysis (JMA) was implemented fairly recently [38] and best suited when both main and interaction effects are present.

Our study was additionally challenged by using a crude readout, BMI, where similar measures can reflect very different physiological status, e.g high BMI could correspond to high visceral fat deposition as well as low visceral fat deposition but high muscle mass. It would certainly benefit from more specific measures of environmental exposures for example, of diet (fructose, fat content, alcohol intake) or amount of physical activity or of metabolic status of the subject.

Despite these limitations, this is the largest investigation of the interplay between genetic variants influencing urate and BMI status to date and it provides novel, biologically supported, hypotheses that warrant further investigations.

Of the known urate loci, there was weak statistical evidence for modulation of *SLC2A9* variant effects by BMI and no support from previous reports [9,16] of a consistent BMI modulating effect. By contrast, statistically significant change was observed for *ABCG2* in men, with a fan-shaped interaction pattern and diminution (by half) of the genetic variant effect size in obese compared to lean men on average. The ATP-binding cassette transporter *ABCG2* has been established as a high capacity urate transporter, is expressed in renal proximal tubules, liver and intestines, and the hyperuricemia causal Q141K mutation has been shown to reduce urate transport rates [39]. Surrounding lipids, ATP concentrations, cholesterol and bile acids have been shown to modulate activity of *ABCG2* in vitro [40]. Interestingly, BMI-dependent effects of Q141K on urate response to acute fructose exposure have been recently reported [41]. A stronger effect of *GCKR* variant in the obese strata was only suggestive but it is well supported by the equivalent doubling in the lowering effect reported for the *GCKR* pleiotropic rs780094 T allele for fasting insulin and glucose in high-BMI participants compared to low-BMI participants, supplementary Table 2 of [32]. It is also consistent with the finding that adjustment for triglyceride (TG) level as potential mediator/confounder attenuates *GCKR* rs780094 variant urate association [10].

RBFOX3 and *EROL1B* were the top loci showing interaction with BMI status using linear models (with *RBFOX3* index SNP reaching genome-wide significance in the combined discovery and look-up studies GWAMA). Both loci displayed the strongest evidence of a significant difference in SNP main effect when the lean and obese stratified samples were compared (S7 Table), analyses in which no individual study showed a high inflation factor or high heterogeneity across studies, supporting genuine interaction with BMI and in a linear fashion. We noted that, in contrast to those, the two top ranking loci from the stratified analyses comparisons (both for men lean-overweight contrasts) were not significantly interacting with BMI when using a linear model of interaction, and would require replication using the same methodology to be confirmed. *RBFOX3* is a neuronal nuclear marker expressed in the Arcuate nucleus in the hypothalamus where orexigenic and anorexigenic neurons reside. Its paralog, *RBFOX1*, has been proposed as an obesity gene [42]. *RBFOX3* (aka *HRNBP3*) was also selected together with 38 other genes in a gene-centric joint test for significant association with HDL-Cholesterol levels in a dataset combining expression data and GWAS data from independent sources [43]. A metabolic outcome of *RBFOX3* knockout in mice (international mouse phenotyping consortium) is decreased circulating alkaline phosphatase, human levels of which correlates with BMI [44] and metabolic syndrome [45], a component of which is

hyperuricemia. *EROL1B* encoding for the endoplasmic reticulum oxidoreductin 1LB catalyzes the formation of disulfite-bonds in the ER. It represents another good candidate for BMI interaction as it is responsive to the unfolded protein response, a signal triggered by ER stress, levels of which are elevated in state of over-nutrition [46]. ER stress response itself may induce inflammation [47] and has been correlated with increased levels of inflammation marker molecules CRP and IL6 which were both positively correlated with urate levels [48].

The “N-glycan biosynthesis” pathway acting to influence urate levels differentially in lean individuals compared to overweight or obese individuals is intriguing. One of the newly identified urate loci [2], *B3GNT4*, also acts in a complex capping reaction, of Type II Lactosamine for example, establishing a precedent for a link between glycosylation enzyme variation and urate levels. The glycolysis intermediate Fructose 6P is the main precursor of amino sugar, combining with glutamine to form glucosamine-6-phosphate. Dependence on glutamine for both purine and glycoaminoglycan biosynthesis as illustrated by the inhibition of either pathway by the glutamine analogue antagonist DON [49] also interconnects these pathways.

These links would be important to study further as glucosamine can be prescribed to patients with gout to reduce pain and inflammation but the possibility that it might influence the urate level has not been explored.

Significant changes in N-glycosylation profiles with BMI have been well documented [50,51,52]. Fitting with the urate-association results (S11 Table), core fucosylation (driven by FUT8) was noted to decrease with BMI [52] and transcript levels for the sialyltransferase gene *ST6GALT2* to be highly stimulated by the pro-inflammatory cytokines IL6 and IL8 [53] that are potentially elevated in the systemic low-grade inflammation that characterises obesity [54]. It is possible that in obese individuals flux towards O-GlcNacylation rather than towards N-glycan biosynthesis is more prominent, possibly following ER stress. O-GlcNacylation has been proposed as a nutrient sensor activated by glucose availability and correlates with insulin resistance, a common hallmark of obesity [55].

Metabolic pathways are highly inter-connected and their dys-regulation underlies many diseases. Accounting for body mass index in analyses provides a tool to link pathways to both obesity and urate homeostasis.

Supporting Information

S1 Fig. Scatter plots of BMI and serum urate in men and women from two populations used in this study. A CROATIA-Vis and B.ORCADES. Residuals from a mixed linear model adjusting serum urate (SU) levels for age and accounting for relatedness are plotted against each other. As noted in [11] the linear fit is stronger amongst women.

(TIF)

S2 Fig. Forest plots for rs7711186 *CLK4* variant effect size in the male and female obese stratum in replication datasets together with those of a *SLC2A9* variant as positive control.

In the discovery dataset, rs7711186 (C allele) was suggestively associated with urate in the men-obese stratum, differentially (overall effect size = 0.21, se = 0.04). Look-up in a small Polynesian study (NZL-Poly) where obesity is prominent is added under the overall meta-analysis value for the replication studies, all of European ancestry (represented by lozenge). *For this Polynesian study only the *SLC2A9* variant rs11942223, in LD ($r^2 = 0.6$) with variant rs13129697, was available and used in the figure.

(TIF)

S3 Fig. QQ plots for difference in SU effect statistics in all nine comparisons performed: lean versus overweight, lean versus obese and overweight versus obese in combined-gender

(ALL) or sex-stratified (MEN, WOMEN) samples. The ordered observed squared t statistic are plotted against the ordered expected statistics of the null, chi², distribution, where $t = (\beta_{\text{bmicat1}} - \beta_{\text{bmicat2}}) / \sqrt{(\text{SE}_{\text{bmicat1}}^2 + \text{SE}_{\text{bmicat2}}^2 - 2r(\text{SE}_{\text{bmicat1}}, \text{SE}_{\text{bmicat2}}))}$, with β_{bmicat} and $\text{SE}_{\text{bmicat}}$ the meta-analysis weighted beta-estimates and their corresponding standard errors and r the Spearman rank correlation coefficient between meta-analyzed beta-estimates in the BMI categories compared across all SNPs. Inflation coefficients, λ_{GC} , are reported for each plot in the left upper corner.

(TIF)

S4 Fig. Forest plots of effect sizes within BMI stratum for variants showing the most significant mean effect size differences (associated P-value, P_{diff}) between BMI stratum genome-wide, in the combined-gender (all) strata. The overall inverse—variance-weighted mean effect per BMI stratum is calculated assuming fixed effect across studies and represented by a lozenge, associated P-value displayed as P. Measure of heterogeneity between studies is reported (I-squared) with associated P-value for significance (p). For study abbreviations and references, see [S1 Table](#).

(TIF)

S1 Table. Study description for each study site.

(DOC)

S2 Table. Individual study summary statistics for serum urate levels (SU) within the nine BMI/gender categories analysed. SU unit is in mg/dl, sd stands for standard deviation, N is the number of individuals with BMI and SU measures.

(XLS)

S3 Table. Study-specific genotyping, imputation information and analysis softwares.

(XLS)

S4 Table. List of inflation factors (λ) for each sub-analysis at individual study level. Inflation factors were calculated after filtering out poorly imputed variants and low frequency variants ($\text{MAF} < 1\%$ for main effect analysis in BMI-stratified GWAS (λ^*), $\text{MAF} < 5\%$ for SNP* BMI interaction term analysis (λ^{**}). NA flags analysis not performed. *** indicates that model-robust regression method was used.

(XLS)

S5 Table. List of loci encompassing SNP(s) with SU association suggestive P-value ($5 \times 10^{-8} = <P < 10^{-5}$) in the nine stratified GWAMA performed. Only the information pertaining to the SNP with the lowest P-value (index SNP) is listed. Lower allele frequency variants ($1\% < \text{MAF} < 5\%$) are reported if the meta-analysis included at least four populations and if the contribution of any single study, as calculated by the meta R package, was lower than 30%. A1, allele for which effect (β) is reported; A2 alternate allele, frq(A1) weighted average effect-allele frequency across studies. Associations reported in the vicinity of the urate index SNP (in a 150kb region centred on the SNP) in the NHGRI GWAS catalogue (29_10_2013 update) are listed; highlighted red, the ones with same index SNP or index SNP in high to moderate linkage disequilibrium ($r^2 > 0.4$).

(XLS)

S6 Table. List of significant and suggestive loci ($P\text{-value} < 10^{-4}$) from the nine BMI stratified GWAMA in the gene-based association test implemented in VEGAS. Novel loci are shaded in grey. In bold, gene reaching genome-wide significant association with serum urate levels ($P < 2.10^{-6}$).

(XLS)

S7 Table. List of loci with SNP(s) displaying the strongest evidence of SU mean effect size difference across BMI strata in the discovery studies. Effect differences were tested using a t test. All loci with SNP displaying a $P_{\text{diff}} < 10^{-5}$ are listed with representative index SNP of lowest P-value (the total number of SNPs with suggestive P-value per loci is listed in N suggestivSNPs column). Low MAF SNPs were filtered as in [S5 Table](#). Additionally, P_{diff} values for the 28 known urate loci [2] are listed with index SNP from the published data. Locus in bold indicates that the difference in effect size between BMI strata reached genome-wide significance. P-value in bold for the known urate loci are those reaching the nominal threshold of 0.05. Locus with asterisk had index SNP with main effect reaching suggestive level of association ($P < 10^{-5}$) in the BMI stratified urate GWAMA analysis ([S5 Table](#)).
(XLS)

S8 Table. List of loci with suggestive ($P_{\text{inter}} < 10^{-5}$) SNPxBMI interaction term using regression based method. Studies with inflation factor greater than 1.2 were not included in the analysis. For the combined-gender analysis, the CoLaus study was analysed as a replication study to balance discovery and replication sets. SNP with low MAF ($< 5\%$) were excluded prior to meta-analysis. Results for the discovery, replication and combined sets are presented. Locus in bold indicates a genome-wide significant interaction effect. Shaded are loci common with [S9 Table](#) (list of loci with suggestive difference in urate main effects between BMI stratified GWAMA)
(XLS)

S9 Table. Results obtained as in [S7 Table](#) when analysis is restricted to the subset of studies (N = 16) used for BMI by SNP interaction testing using a regression-based method and with markers of MAF > 5% for direct comparison. Shaded are loci displaying suggestive association in linear interaction model(listed in [S8 Table](#)).
(XLS)

S10 Table. Results from the Pathway analysis tool implemented in the genomicper R package in the nine stratified urate GWAMA performed.
(XLS)

S11 Table. List of genes in the KEGGs N-glycan biosynthesis pathway, hsa00510, harbouring at least one SNP with a serum urate GWAMA P-value (P) nominally significant in one of the three combined-gender BMI categories analysed. N-glycan biosynthesis step coded 1 = N-glycan lipid-linked oligosaccharide precursor synthesis 2 = high mannose oligosaccharide to an Asparagine residue transfer and N-glycan trimming and branching 3 = more elaborate capping reactions
(XLS)

Acknowledgments

Each study thanks the general practitioners, clinicians, team members and participants for their invaluable contributions. Specific additional acknowledgments are listed below.

BRIGHT: The BRIGHT study is extremely grateful to the BRIGHT nursing team and we would also to thank Charles Mein, Richard Dobson, Chris Wallace and the Barts and The London Genome Centre staff. This is part of the translational studies supported by Barts and the London and the Leicester National Institute for Health Research Cardiovascular Biomedical Research Units. This work forms part of the CHAPTER e-health centre research program.

CoLaus: The authors thank Dawn Waterworth and Vincent Mooser, Co-Pis of the CoLaus study. Special thanks to Sven Bergmann, Jacqui Beckmann, Yolande Barreau, Mathieu

Firmann, Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagate, Jeanne Ecoffey and Sylvie Mermoud for data collection.

CROATIA-Korcula: We acknowledge Peter Lichtner and the Helmholtz Zentrum München genotyping staff (Munich, Germany) for the SNP genotyping.

CROATIA-Vis: We acknowledge Prof. Pavao Rudan, Dr. Nina Smolej-Narancic, Dr. Branka Janicijevic and their colleagues at the Institute for Anthropological Research 10000 Zagreb, Croatia, for participants' recruitment and field work, the Wellcome Trust Clinical Research Facility (Edinburgh) for performing the initial SNP genotyping.

ERF: We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

EGCUT: We acknowledge EGCUT personnel, especially Mr. V. Soo. Data analyzes were carried out in part in the High Performance Computing Center of University of Tartu.

INGI_CILENTO: We thank the populations of Cilento for their participation in the study.

INGI-Carlantino and INGI-FVG: We thank Laura Esposito and Angela D'Eustacchio for technical support. We are very grateful to the municipal administrators for their collaboration on the project and for logistic support. We would like to thank all participants to this study.

INGI-Val Borbera: We acknowledge the inhabitants of the Val Borbera who accepted to participate in the study and the collaboration of the local administrators and of ASL-A1, Novi Ligure (A1). We also acknowledge the support of Prof. Clara Camaschella and Federico Caligaris-Cappio (U. Vita e Salute-HSR) for clinical data collection and of Fiammetta Viganò for technical help.

MICROS: For the MICROS study, we thank the primary care practitioners Raffaella Stocker, Stefan Waldner, Toni Pizzocco, Josef Plangger, Ugo Marcadent, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project.

NSPHS: The authors are grateful for the contribution of district nurse Svea Hennix for data collection and Inger Jonasson for logistics and coordination of the health survey. Finally, the authors thank all the community participants for their interest and willingness to contribute to the study.

Ogliastro Genetic Park (OGP): We thank the Ogliastro population and all the individuals who participated in this study. We are very grateful to the municipal administrators for their collaboration to the project and for economic and logistic support.

ORCADES: DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of Lorraine Anderson and the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney.

RS-I, RS-II: We thank Pascal Arp, Mila Jhamai, Dr Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The authors are very grateful to the participants and staff from the Rotterdam Study, the participating general practitioners and the pharmacists. We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid.

SHIP: The SHIP authors are grateful to Mario Stanke for the opportunity to use his Server Cluster for SNP Imputation.

TwinsUK: SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR.

NZPoly: We would like to thank Marilyn Merriman, Ruth Topless, Gabrielle Sexton, Jill James and Roddi Laurence for assistance in recruitment and laboratory work.

Author Contributions

Conceived and designed the experiments: JEH VV. Performed the experiments: JH EA ATeu MM KK TJ ZK NP GP LL TH PS AGo ML TT ADehghan DR GM AVS IMN LP APG LB TE JFP VV. Analyzed the data: JH EA ATeu MM KK TJ ZK NP GP LML TH PS AGo ML TT ADehghan DR GM AVS IMN LP APG LB TE JFP VV. Contributed reagents/materials/analysis tools: PN AsJ AAH OP SEH FM SHW ATen ATin EM AGr GKG JC PD'A SU PV GW SC IK KF MV JM CM ET CB RS ADöring ER KS AHo AGU MW H-EW GD AJG ND LS JHS MK RN MN CIS KB SMF ET AnJ VS CinS CHe MBu RM NK SK SS SR SC NS GH TN PBM CHa AK CaH CC. Wrote the paper: JH EA ATeu MM KK TJ ZK NP GP LML TH PS AGo ML TT ADehghan DR GM AVS IMN LP APG LB PN AsJ AAH OP TE JFP SEH FM SHW ATen ATin EM AGr GKG JC PD'A SU PV GW SC IK KF MV JEM CM ET CB RS ADöring ER KS AHo AGU MW H-EW GD AJG ND LS JHS MK RN MN CIS KB SMF ET AnJ VS CinS CHe MBu RM NK SK SS SR SC NS GH TN PBM NH HC IR CHa OHF TRM VG MPi BWP HS AM MCi PPP CMvD LF GG IJD MGD JFW PG UG TDS AFW CaH HW MPe MBo WHLK MCa DT HV CG AK VV. Design and/or management of individual study: NH HC IR OHF TRM VG MPi BWP HS AM MCi PPP CMvD LF GG IJD MGD JFW PG UG TDS AFW CaH HW MPe MBo WHLK MCa DT HV CG.

References

1. Kutzin MK, Firestein BL. Altered uric acid levels and disease states. *J Pharmacol Exp Ther*. 2008; 324: 1–7. PMID: [17890445](#)
2. Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet*. 2013; 45: 145–154. doi: [10.1038/ng.2500](#) PMID: [23263486](#)
3. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. *Nat Genet*. 2008; 40: 437–442. doi: [10.1038/ng.106](#) PMID: [18327257](#)
4. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. *Nat Genet*. 2008; 40: 430–436. doi: [10.1038/ng.107](#) PMID: [18327256](#)
5. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. *Lancet*. 2008; 372: 1953–1961. doi: [10.1016/S0140-6736\(08\)61343-4](#) PMID: [18834626](#)
6. Zhang L, Spencer KL, Voruganti VS, Jorgensen NW, Fornage M, Best LG, et al. Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. *Am J Epidemiol*. 2013; 177: 923–932. doi: [10.1093/aje/kws330](#) PMID: [23552988](#)
7. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, et al. Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations. *Plos Genetics*. 2009; 5: e1000504. doi: [10.1371/journal.pgen.1000504](#) PMID: [19503597](#)
8. Voruganti VS, Nath SD, Cole SA, Thameem F, Jowett JB, Bauer R, et al. Genetics of variation in serum uric acid and cardiovascular risk factors in Mexican Americans. *J Clin Endocrinol Metab*. 2009; 94: 632–638. doi: [10.1210/jc.2008-0682](#) PMID: [19001525](#)
9. Brandstatter A, Kiechl S, Kollerits B, Hunt SC, Heid IM, Coassin S, et al. Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. *Diabetes Care*. 2008; 31: 1662–1667. doi: [10.2337/dc08-0349](#) PMID: [18487473](#)
10. van der Harst P, Bakker SJ, de Boer RA, Wolfenbutter BH, Johnson T, Caulfield MJ, et al. Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. *Hum Mol Genet*. 2010; 19: 387–395. doi: [10.1093/hmg/ddp489](#) PMID: [19861489](#)
11. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. *J Zhejiang Univ Sci B*. 2007; 8: 593–598. PMID: [17657863](#)

12. Alatalo PI, Koivisto HM, Hietala JP, Bloigu RS, Niemela OJ. Gender-dependent impacts of body mass index and moderate alcohol consumption on serum uric acid—an index of oxidant stress status? *Free Radic Biol Med.* 2009; 46: 1233–1238. doi: [10.1016/j.freeradbiomed.2009.02.002](https://doi.org/10.1016/j.freeradbiomed.2009.02.002) PMID: [19439211](https://pubmed.ncbi.nlm.nih.gov/19439211/)
13. Choi HK, Zhang Y. Bariatric surgery as urate-lowering therapy in severe obesity. *Ann Rheum Dis.* 2014; 73: 791–793. doi: [10.1136/annrheumdis-2013-204861](https://doi.org/10.1136/annrheumdis-2013-204861) PMID: [24706555](https://pubmed.ncbi.nlm.nih.gov/24706555/)
14. Obeid OA. Low phosphorus status might contribute to the onset of obesity. *Obes Rev.* 2013; 14: 659–664. doi: [10.1111/obr.12039](https://doi.org/10.1111/obr.12039) PMID: [23679666](https://pubmed.ncbi.nlm.nih.gov/23679666/)
15. Nair S, V PC, Arnold C, Diehl AM. Hepatic ATP reserve and efficiency of replenishing: comparison between obese and nonobese normal individuals. *Am J Gastroenterol.* 2003; 98: 466–470. PMID: [12591070](https://pubmed.ncbi.nlm.nih.gov/12591070/)
16. Li WD, Jiao H, Wang K, Zhang CK, Glessner JT, Grant SF, et al. A genome wide association study of plasma uric acid levels in obese cases and never-overweight controls. *Obesity (Silver Spring).* 2013; 21: E490–494. doi: [10.1002/oby.20303](https://doi.org/10.1002/oby.20303) PMID: [23703922](https://pubmed.ncbi.nlm.nih.gov/23703922/)
17. Hollis-Moffatt JE, Phipps-Green AJ, Chapman B, Jones GT, van Rij A, Gow PJ, et al. The renal urate transporter SLC17A1 locus: confirmation of association with gout. *Arthritis Res Ther.* 2012; 14: R92. doi: [10.1186/ar3816](https://doi.org/10.1186/ar3816) PMID: [22541845](https://pubmed.ncbi.nlm.nih.gov/22541845/)
18. Chen WM, Abecasis GR. Family-based association tests for genomewide association scans. *Am J Hum Genet.* 2007; 81: 913–926. PMID: [17924335](https://pubmed.ncbi.nlm.nih.gov/17924335/)
19. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. *Bioinformatics.* 2007; 23: 1294–1296. PMID: [17384015](https://pubmed.ncbi.nlm.nih.gov/17384015/)
20. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* 2014; 42: D1001–1006. doi: [10.1093/nar/gkt1229](https://doi.org/10.1093/nar/gkt1229) PMID: [24316577](https://pubmed.ncbi.nlm.nih.gov/24316577/)
21. Voorman A, Lumley T, McKnight B, Rice K. Behavior of QQ-plots and genomic control in studies of gene-environment interaction. *Plos One.* 2011; 6: e19416. doi: [10.1371/journal.pone.0019416](https://doi.org/10.1371/journal.pone.0019416) PMID: [21589913](https://pubmed.ncbi.nlm.nih.gov/21589913/)
22. Cabrera CP, Navarro P, Huffman JE, Wright AF, Hayward C, Campbell H, et al. Uncovering networks from genome-wide association studies via circular genomic permutation. *G3 (Bethesda).* 2012; 2: 1067–1075. doi: [10.1534/g3.112.002618](https://doi.org/10.1534/g3.112.002618) PMID: [22973544](https://pubmed.ncbi.nlm.nih.gov/22973544/)
23. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. *Circ Cardiovasc Genet.* 2010; 3: 523–530. doi: [10.1161/CIRCGENETICS.109.934455](https://doi.org/10.1161/CIRCGENETICS.109.934455) PMID: [20884846](https://pubmed.ncbi.nlm.nih.gov/20884846/)
24. Charles BA, Shriner D, Doumatey A, Chen G, Zhou J, Huang H, et al. A genome-wide association study of serum uric acid in African Americans. *BMC Med Genomics.* 2011; 4: 17. doi: [10.1186/1755-8794-4-17](https://doi.org/10.1186/1755-8794-4-17) PMID: [21294900](https://pubmed.ncbi.nlm.nih.gov/21294900/)
25. Fox CS, Liu Y, White CC, Feitosa M, Smith AV, Heard-Costa N, et al. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. *PLoS Genet.* 2012; 8: e1002695. doi: [10.1371/journal.pgen.1002695](https://doi.org/10.1371/journal.pgen.1002695) PMID: [22589738](https://pubmed.ncbi.nlm.nih.gov/22589738/)
26. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. *Plos One.* 2012; 7: e51954. doi: [10.1371/journal.pone.0051954](https://doi.org/10.1371/journal.pone.0051954) PMID: [23251661](https://pubmed.ncbi.nlm.nih.gov/23251661/)
27. Chu AY, Workalemahu T, Paynter NP, Rose LM, Giulianini F, Tanaka T, et al. Novel locus including FGF21 is associated with dietary macronutrient intake. *Hum Mol Genet.* 2013; 22: 1895–1902. doi: [10.1093/hmg/ddt032](https://doi.org/10.1093/hmg/ddt032) PMID: [23372041](https://pubmed.ncbi.nlm.nih.gov/23372041/)
28. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, et al. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. *Mol Endocrinol.* 2013; 27: 657–670. doi: [10.1210/me.2012-1397](https://doi.org/10.1210/me.2012-1397) PMID: [23518928](https://pubmed.ncbi.nlm.nih.gov/23518928/)
29. Thomas D. Gene-environment-wide association studies: emerging approaches. *Nat Rev Genet.* 2010; 11: 259–272. doi: [10.1038/nrg2764](https://doi.org/10.1038/nrg2764) PMID: [20212493](https://pubmed.ncbi.nlm.nih.gov/20212493/)
30. Smith PG, Day NE. The design of case-control studies: the influence of confounding and interaction effects. *Int J Epidemiol.* 1984; 13: 356–365. PMID: [6386716](https://pubmed.ncbi.nlm.nih.gov/6386716/)
31. Kilpelainen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med.* 2011; 8: e1001116. doi: [10.1371/journal.pmed.1001116](https://doi.org/10.1371/journal.pmed.1001116) PMID: [22069379](https://pubmed.ncbi.nlm.nih.gov/22069379/)
32. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat Genet.* 2012; 44: 659–669. doi: [10.1038/ng.2274](https://doi.org/10.1038/ng.2274) PMID: [22581228](https://pubmed.ncbi.nlm.nih.gov/22581228/)
33. Velez Edwards DR, Naj AC, Monda K, North KE, Neuhaus M, Magvanjav O, et al. Gene-environment interactions and obesity traits among postmenopausal African-American and Hispanic women in the

- Women's Health Initiative SHARe Study. *Hum Genet.* 2013; 132: 323–336. doi: [10.1007/s00439-012-1246-3](https://doi.org/10.1007/s00439-012-1246-3) PMID: [23192594](https://pubmed.ncbi.nlm.nih.gov/23192594/)
34. Hancock DB, Artigas MS, Gharib SA, Henry A, Manichaikul A, Ramasamy A, et al. Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. *PLoS Genet.* 2012; 8: e1003098. doi: [10.1371/journal.pgen.1003098](https://doi.org/10.1371/journal.pgen.1003098) PMID: [23284291](https://pubmed.ncbi.nlm.nih.gov/23284291/)
 35. Perry JR, Voight BF, Yengo L, Amin N, Dupuis J, Ganser M, et al. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. *PLoS Genet.* 2012; 8: e1002741. doi: [10.1371/journal.pgen.1002741](https://doi.org/10.1371/journal.pgen.1002741) PMID: [22693455](https://pubmed.ncbi.nlm.nih.gov/22693455/)
 36. Randall JC, Winkler TW, Kutalik Z, Berndt SI, Jackson AU, Monda KL, et al. Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. *PLoS Genet.* 2013; 9: e1003500. doi: [10.1371/journal.pgen.1003500](https://doi.org/10.1371/journal.pgen.1003500) PMID: [23754948](https://pubmed.ncbi.nlm.nih.gov/23754948/)
 37. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. *PLoS Genet.* 2011; 7: e1002237. doi: [10.1371/journal.pgen.1002237](https://doi.org/10.1371/journal.pgen.1002237) PMID: [21876681](https://pubmed.ncbi.nlm.nih.gov/21876681/)
 38. Manning AK, LaValley M, Liu CT, Rice K, An P, Liu Y, et al. Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP x environment regression coefficients. *Genet Epidemiol.* 2011; 35: 11–18. doi: [10.1002/gepi.20546](https://doi.org/10.1002/gepi.20546) PMID: [21181894](https://pubmed.ncbi.nlm.nih.gov/21181894/)
 39. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. *Proc Natl Acad Sci U S A.* 2009; 106: 10338–10342. doi: [10.1073/pnas.0901249106](https://doi.org/10.1073/pnas.0901249106) PMID: [19506252](https://pubmed.ncbi.nlm.nih.gov/19506252/)
 40. Telbisz A, Ozvegy-Laczka C, Hegedus T, Varadi A, Sarkadi B. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. *Biochem J.* 2013; 450: 387–395. doi: [10.1042/BJ20121485](https://doi.org/10.1042/BJ20121485) PMID: [23205634](https://pubmed.ncbi.nlm.nih.gov/23205634/)
 41. Dalbeth N, House ME, Gamble GD, Pool B, Horne A, Purvis L, et al. Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge. *Arthritis Res Ther.* 2014; 16: R34. doi: [10.1186/ar4463](https://doi.org/10.1186/ar4463) PMID: [24476385](https://pubmed.ncbi.nlm.nih.gov/24476385/)
 42. McNally T, Huang Q, Janis RS, Liu Z, Olejniczak ET, Reilly RM. Structural analysis of UBL5, a novel ubiquitin-like modifier. *Protein Sci.* 2003; 12: 1562–1566. PMID: [12824502](https://pubmed.ncbi.nlm.nih.gov/12824502/)
 43. Charlesworth JC, Peralta JM, Drigalenko E, Goring HH, Almasy L, Dyer TD et al. Toward the identification of causal genes in complex diseases: a gene-centric joint test of significance combining genomic and transcriptomic data. *BMC Proc* 3 Suppl. 2009; 7: S92. PMID: [20018089](https://pubmed.ncbi.nlm.nih.gov/20018089/)
 44. Ali AT, Paiker JE, Crowther NJ. The relationship between anthropometry and serum concentrations of alkaline phosphatase isoenzymes, liver-enzymes, albumin, and bilirubin. *Am J Clin Pathol.* 2006; 126: 437–442. PMID: [16880138](https://pubmed.ncbi.nlm.nih.gov/16880138/)
 45. Kim MK, Baek KH, Kang MI, Park SE, Rhee EJ, Park CY, et al. Serum alkaline phosphatase, body composition, and risk of metabolic syndrome in middle-aged Korean. *Endocr J.* 2013; 60: 321–328. PMID: [23149655](https://pubmed.ncbi.nlm.nih.gov/23149655/)
 46. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell.* 2010; 140: 900–917. doi: [10.1016/j.cell.2010.02.034](https://doi.org/10.1016/j.cell.2010.02.034) PMID: [20303879](https://pubmed.ncbi.nlm.nih.gov/20303879/)
 47. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced inflammation: does it aid or impede disease progression? *Trends Mol Med.* 2012; 18: 589–598. doi: [10.1016/j.molmed.2012.06.010](https://doi.org/10.1016/j.molmed.2012.06.010) PMID: [22883813](https://pubmed.ncbi.nlm.nih.gov/22883813/)
 48. Lyngdoh T, Marques-Vidal P, Paccaud F, Preisig M, Waeber G, Bochud M, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. *Plos One.* 2011; 6: e19901. doi: [10.1371/journal.pone.0019901](https://doi.org/10.1371/journal.pone.0019901) PMID: [21625475](https://pubmed.ncbi.nlm.nih.gov/21625475/)
 49. Greene RM, Kochhar DM. Limb development in mouse embryos: protection against teratogenic effects of 6-diazo-5-ox-L-norleucine (DON) in vivo and in vitro. *J Embryol Exp Morphol.* 1975; 33: 355–370. PMID: [1176851](https://pubmed.ncbi.nlm.nih.gov/1176851/)
 50. Knezevic A, Gornik O, Polasek O, Pucic M, Redzic I, Novokmet M, et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. *Glycobiology.* 2010; 20: 959–969. doi: [10.1093/glycob/cwq051](https://doi.org/10.1093/glycob/cwq051) PMID: [20356825](https://pubmed.ncbi.nlm.nih.gov/20356825/)
 51. Nikolac Perkovic M, Pucic Bakovic M, Kristic J, Novokmet M, Huffman JE, Vitart V, et al. The association between galactosylation of immunoglobulin G and body mass index. *Prog Neuropsychopharmacol Biol Psychiatry.* 2014; 48: 20–25. doi: [10.1016/j.pnpbp.2013.08.014](https://doi.org/10.1016/j.pnpbp.2013.08.014) PMID: [24012618](https://pubmed.ncbi.nlm.nih.gov/24012618/)
 52. Lu JP, Knezevic A, Wang YX, Rudan I, Campbell H, Zou ZK, et al. Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese Han and Croatian populations. *J Proteome Res.* 2011; 10: 4959–4969. doi: [10.1021/pr2004067](https://doi.org/10.1021/pr2004067) PMID: [21939225](https://pubmed.ncbi.nlm.nih.gov/21939225/)

53. Groux-Degroote S, Krzewinski-Recchi MA, Cazet A, Vincent A, Lehoux S, Lafitte JJ, et al. IL-6 and IL-8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx epitopes in the human bronchial mucosa. *Biochem J.* 2008; 410: 213–223. PMID: [17944600](#)
54. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. *Int J Obes Relat Metab Disord.* 2004; 28: 993–997. PMID: [15211360](#)
55. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. *Am J Physiol Endocrinol Metab.* 2006; 290: E1–E8. PMID: [16339923](#)